

**COMPARATIVE STUDY BETWEEN *DHFR* AND *DHPS*
GENES IN *PLASMODIUM FALCIPARUM*,
PLASMODIUM VIVAX AND *PLASMODIUM*
KNOWLESI ISOLATED FROM SABAH**



NOR AFIZAH BINTI NUIN

UMS
UNIVERSITI MALAYSIA SABAH

**BIOTECHNOLOGY RESEARCH INSTITUTE
UNIVERSITI MALAYSIA SABAH
2016**

**COMPARATIVE STUDY BETWEEN *DHFR* AND *DHPS*
GENES IN *PLASMODIUM FALCIPARUM*,
PLASMODIUM VIVAX AND *PLASMODIUM*
KNOWLESI ISOLATED FROM SABAH**

NOR AFIZAH BINTI NUIN

**DISSERTATION SUBMITTED IN FULFILLMENT FOR
THE DEGREE OF MASTER OF SCIENCE
(BIOTECHNOLOGY)**

**BIOTECHNOLOGY RESEARCH INSTITUTE
UNIVERSITI MALAYSIA SABAH
2016**

UNIVERSITI MALAYSIA SABAH

BORANG PENGESAHAN TESIS

JUDUL : _____

IJAZAH : _____

SAYA : _____ SESI PENGAJIAN : _____

(HURUF BESAR)

Mengaku membenarkan tesis *(LPSM/Sarjana/Doktor Falsafah) ini disimpan di Perpustakaan Universiti Malaysia Sabah dengan syarat-syarat kegunaan seperti berikut:-

1. Tesis adalah hak milik Universiti Malaysia Sabah.
2. Perpustakaan Universiti Malaysia Sabah dibenarkan membuat salinan untuk tujuan pengajian sahaja.
3. Perpustakaan dibenarkan membuat salinan tesis ini sebagai bahan pertukaran antara institusi pengajian tinggi.
4. Sila tandakan (/)

SULIT (Mengandungi maklumat yang berdarjah keselamatan atau kepentingan Malaysia seperti yang termaktub di AKTA RAHSIA RASMI 1972)

TERHAD (Mengandungi maklumat TERHAD yang telah ditentukan oleh organisasi/badan di mana penyelidikan dijalankan)

TIDAK TERHAD

Disahkan oleh:

(TANDATANGAN PENULIS)_____
(TANDATANGAN PUSTAKAWAN)

Alamat Tetap: _____

TARIKH: _____

(NAMA PENYELIA)

TARIKH: _____

Catatan:

*Potong yang tidak berkenaan.

*Jika tesis ini SULIT dan TERHAD, sila lampirkan surat daripada pihak berkuasa/organisasi berkenaan dengan menyatakan sekali sebab dan tempoh tesis ini perlu dikelaskan sebagai SULIT dan TERHAD.

*Tesis dimaksudkan sebagai tesis bagi Ijazah Doktor Falsafah dan Sarjana Secara Penyelidikan atau disertai bagi pengajian secara kerja kursus dan Laporan Projek Sarjana Muda (LPSM).

DECLARATION

I hereby declare that the material in this thesis is my own except for quotations, summaries and references which have been duly acknowledged.

9th September 2016

Nor Afizah Binti Nuin

MZ1211008T



UMS
UNIVERSITI MALAYSIA SABAH

CERTIFICATION


NAMA : **NOR AFIZAH BINTI NUIN**

MATRIC : **MZ1211008T**

TITLE : **COMPARATIVE STUDY BETWEEN *DHFR* AND *DHPS* GENES
IN *PLASMODIUM FALCIPARUM*, *PLASMODIUM VIVAX* AND
PLASMODIUM KNOWLESI ISOLATED FROM SABAH**

DEGREE : **MASTER OF SCIENCE (BIOTECHNOLOGY)**

VIVA DATE : **3RD AUGUST 2016**



DECLARED BY;
UNIVERSITI MALAYSIA SABAH

1. MAIN SUPERVISOR

Lau Tiek Ying

Signature

2. CO-SUPERVISOR

Prof. Dr. Clemente Michael Wong Vui Ling

ACKNOWLEDGEMENTS

Foremost, I am really thankful to God for all His blessings. Next, I would like to thank my supervisor, Mdm. Sophia Lau Tiek Ying for her patience in teaching me and for her continuous guidance and supports throughout my study. Also, thanks to my co-supervisor Prof. Dr. Clemente Michael Wong for his precious comments and suggestions.

I would also like to thank all the lecturers who were involved in the BRI Postgraduate Seminars for their questions, comments and suggestions in order to help and improve the student's research progress.

I am also grateful to all who were involved in helping me directly or indirectly during this study. Many thanks to those who were involved in providing samples for this study, my course mates, lab mates, lab technicians and staffs of BRI for their continuous support, help and sharing knowledge.

Finally, I must express my greatest gratitude to my beloved family members, my parents, my siblings and all my friends for their understanding, encouragement, moral supports and love. Thank you very much.

Nor Afizah Binti Nuin

9th September 2016

ABSTRACT

Malaria is one of the globally challenging parasitic infectious diseases. Treatment failure due to resistance in malaria parasites is an important factor in the effective treatment of malaria. Dihydrofolate reductase (*dhfr*) and dihydropteroate synthase (*dhps*) are two genes that encode the enzymes involved in the folate pathway targeted by antifolate drugs. This study was performed to compare molecular analysis of these two genes in three most prevalent human *Plasmodium* parasites in Sabah namely *P. falciparum*, *P. vivax* and *P. knowlesi*. The genes *dhfr* and *dhps* were amplified and sequenced from PCR confirmed single infection isolates of *P. falciparum*, *P. vivax* and *P. knowlesi*. The sequences were analysed using DNASTAR and MEGA6 softwares. Among 228 samples collected, 70 of them were *P. falciparum* positive, 11 were *P. vivax*, 5 were *P. malariae* and 67 *P. knowlesi* monoinfection. DNA sequence alignment of *dhfr* gene among Sabah isolates was highly conserved in *P. falciparum* and *P. vivax* while *P. knowlesi* demonstrated polymorphisms in about 4% of the full-length *pkdhfr*. Meanwhile, the same rates were also observed in *dhps* gene of which *P. falciparum* and *P. vivax* showed less number of nucleotide polymorphisms than in *P. knowlesi*. Haplotyping analysis at positions which mutations significantly reduce antifolate drug sensitivity revealed identification of 4 *pkdhfr-pkdhps* (2.8% of AIRNI-SGKAA, 69.4% of ANRNI-SGKAA, 25% of ANRNI-SGKGA and 2.8% of ANRNL-SGTGA) while only 2 *pvdhfr-pvdhps* FR TNI-SAKAV (33.3%) and LRMTI-SGKAV (33.3%) type in the study areas. With respect to *P. knowlesi*, the *dhfr* orthologues haplotyping analysis showed wild-type sequence (ANSSI) at this locus. At present, there is no report in *pkdhps* gene mutation conferring resistance has been described in *P. knowlesi*. However, nucleotide polymorphisms observed in *pkdhfr* and *pkdhps* from Sabah isolates could have resulted from the selection of *P. knowlesi* populations with drug resistance alleles under continuous drug pressure indicating the possible presence of human-to-human transmission. This study also shows a remarkably high prevalence of mutations linked to drug resistance in *P. falciparum* and *P. vivax* which highlights the molecular study of polymorphisms in *dhfr* and *dhps* genes remain as a useful tool to monitor the emergence and spread of antifolate drug resistance in malaria parasites from Sabah isolates.

ABSTRAK

Kajian perbandingan di antara gen dhfr dan dhps di dalam Plasmodium falciparum, Plasmodium vivax dan Plasmodium knowlesi pencilan dari Sabah

Malaria merupakan salah satu penyakit berjangkit disebabkan oleh parasit yang merupakan cabaran kepada seluruh dunia. Kegagalan rawatan disebabkan oleh rintangan dalam parasit malaria merupakan factor penting untuk merawat malaria secara berkesan. Dihydrofolate reductase (dhfr) dan dihydropteroate synthase (dhps) adalah dua gen yang terlibat dalam laluan folat yang disasarkan oleh dadah antifolate. Kajian ini telah dijalankan untuk membandingkan analisis molekul kedua-dua gen di dalam tiga jenis parasit Plasmodium yang menjangkiti manusia yang paling lazim di Sabah iaitu *P. falciparum*, *P. vivax* dan *P. knowlesi*. Gen dhfr dan dhps telah diamplifikasi dan penjujukan DNA telah dibuat dari pencilan yang mempunyai jangkitan tunggal *P. falciparum*, *P. vivax* dan *P. knowlesi*. Jujukan-jujukan telah dianalisis menggunakan perisian DNASTAR dan MEGA6. Di antara 228 sampel yang telah diambil, 70 daripadanya adalah positif untuk *P. falciparum*, 11 adalah *P. vivax*, 5 *P. malariae* dan 67 *P. knowlesi*. Urutan penjajaran DNA bagi gen dhfr di kalangan pencilan dari Sabah menunjukkan persamaan yang tinggi di dalam *P. falciparum* dan *P. vivax* manakala *P. knowlesi* menunjukkan kira-kira 4% polimorfisma daripada keseluruhan gen p_{kd}dhfr. Sementara itu, kadar yang sama juga terdapat pada gen dhps di mana *P. falciparum* dan *P. vivax* menunjukkan jumlah polimorfisma yang kurang berbanding yang terdapat di dalam *P. knowlesi*. Analisis haplotaip pada kedudukan di mana mutasi dapat mengurangkan sensitivity dadah antifolat telah menunjukkan bahawa terdapat 4 jenis p_{fd}dhfr-p_{fd}dhps (2.8% adalah **AIRNI-SGKAA**, 69.4% adalah **ANRNI-SGKAA**, 25% adalah **ANRNI-SGKGA** dan 2.8% adalah **ANRNL-SGTGA**) manakala hanya 2 jenis p_{vd}dhfr-p_{vd}dhps iaitu **FRTNI-SAKAV** (33.3%) dan **LRMTI-SGKAV** (33.3%) yang terdapat di kawasan kajian. Berkenaan dengan *P. knowlesi*, analisis gen ortolog dhfr menunjukkan tiada perubahan pada haplotaip asal (ANSSI) pada lokus ini. Sehingga kini, tidak terdapat laporan mengenai mutasi pada gen dhps yang menyebabkan rintangan di dalam *P. knowlesi*. Walaubagaimanapun, polimorfisma nukleotida yang diperhatikan dalam gen p_{kd}dhfr dan p_{kd}dhps di kalangan pencilan dari Sabah boleh terjadi disebabkan pemilihan oleh populasi *P. knowlesi* terhadap alel-alel rintangan dadah di bawah tekanan dadah yang berterusan yang menunjukkan kebarangkalian terdapat pemindahan jangkitan dari manusia ke manusia. Kajian ini juga menunjukkan kelaziman mutasi yang tinggi yang dikaitkan dengan rintangan terhadap dadah di dalam *P. falciparum* dan *P. vivax* yang mana telah mengetengahkan kajian molekul polimorfisma di dalam gen dhfr dan dhps kekal sebagai kaedah yang berguna bagi

memantau kemunculan dan penyebaran rintangan terhadap dadah antifolat di kalangan parasit malaria di Sabah.

LIST OF CONTENTS

	Page
TITLE	I
DECLARATION	Ii
CERTIFICATION	Iii
ACKNOWLEDGEMENT	Iv
ABSTRACT	V
<i>ABSTRAK</i>	vi
LIST OF CONTENTS	vii
LIST OF TABLES	xii
LIST OF FIGURES	xiv
LIST OF PHOTOS	xvi
LIST OF APPENDIX	xvii
LIST OF SYMBOLS AND ABBREVIATIONS	xviii
CHAPTER 1: INTRODUCTION	
1.1 Background of Research	1
1.2 Antimalarials: Facing The Problem	2
1.3 Research Questions	3
1.4 Hypothesis of The Study	3
1.5 Objectives of The Study	4
1.6 Significance of The Study	4
CHAPTER 2: LITERATURE REVIEW	
2.1 Global Incidence of Malaria	5
2.1.1 Incidence of malaria in Malaysia	6
2.2 Human <i>Plasmodium</i> Species	7

2.2.1	<i>Plasmodium falciparum</i>	8
2.2.2	<i>Plasmodium vivax</i>	9
2.2.3	<i>Plasmodium malariae</i>	10
2.2.4	<i>Plasmodium ovale</i>	12
2.2.5	<i>Plasmodium knowlesi</i>	13
2.3	Life Cycle of Malarial Parasites	14
2.4	Treatment of Malaria	16
2.5	Sulphadoxine-Pyrimethamine In The Treatment of Malaria	18
2.5.1	Spread of sulphadoxine-pyrimethamine resistance	20
2.6	Mechanisms of Sulphadoxine-Pyrimethamine Resistance And Their Related Genes	21
2.6.1	Mutation conferring resistance to sulphadoxine-pyrimethamine in <i>Plasmodium falciparum</i>	22
2.6.2	Mutation conferring resistance to sulphadoxine-pyrimethamine in <i>Plasmodium vivax</i>	24
2.7	Susceptibility of Antimalarials In Treatment of Human <i>Plasmodium knowlesi</i>	25
CHAPTER 3: MATERIALS AND METHODOLOGY		
3.1	Study Site	28
3.2	Blood Sample Collection	29
3.3	DNA Extraction From Dried Blood Spots	30
3.4	Nested Polymerase Chain Reaction For <i>Plasmodium</i> Species Confirmation	31
3.4.1	Nest 1 <i>Plasmodium</i> genus-specific PCR amplification reactions	31
3.4.2	Nest 2 <i>Plasmodium</i> genus-specific PCR amplification reactions	32
3.4.3	Nest 2 <i>Plasmodium</i> species-specific PCR amplification reactions	32
3.5	Primer Design For The Amplification of <i>dhfr</i> And <i>dhps</i> Genes In	34


	<i>P. vivax</i> And <i>P. knowlesi</i>	
3.6	PCR Amplification of <i>dhfr</i> And <i>dhps</i> Genes In <i>Plasmodium</i> sp.	35
3.5.1	Nested PCR amplification of <i>dhfr</i> and <i>dhps</i> in <i>P. falciparum</i>	36
3.5.2	Nested PCR amplification of <i>dhfr</i> and <i>dhps</i> in <i>P. vivax</i>	38
3.5.3	Nested PCR amplification of <i>dhfr</i> and <i>dhps</i> in <i>P. knowlesi</i>	39
3.7	Gel Electrophoresis	41
3.8	Gel Extraction of PCR Amplification Product	41
3.9	Direct DNA Sequencing	42
3.10	Computer-Assisted Sequence Data Analysis	42
3.10.1	Sequence assembly and alignment	43
3.10.2	DNA sequence polymorphisms analysis	43
3.10.3	Comparative analysis of sequences from Sabah isolates with other geographical regions	44
CHAPTER 4: RESULTS		
4.1	Study Population	45
4.2	Amplification of Dihydrofolate Reductase (<i>dhfr</i>) And Dihydropteroate Synthase (<i>dhps</i>) Genes In <i>Plasmodium</i> Sp. By Nested PCR	50
4.3	Analysis of Dihydrofolate Reductase (<i>dhfr</i>) And Dihydropteroate Synthase (<i>dhps</i>) Genes In <i>Plasmodium falciparum</i> From Sabah Isolates	52
4.3.1	Sequence polymorphisms of <i>Plasmodium falciparum dhfr</i> (<i>pfdhfr</i>) gene	53
4.3.2	Sequence polymorphisms of <i>Plasmodium falciparum dhps</i> (<i>pfdhps</i>) gene	57
4.3.3	Prevalence of haplotype conferring resistance in dihydrofolate reductase (<i>dhfr</i>) and dihydropteroate synthase (<i>dhps</i>) genes of <i>P. falciparum</i>	61

4.3.4	Comparison of haplotype-conferring resistant in <i>dhfr</i> and <i>dhps</i> genes of <i>P. falciparum</i> from Sabah isolates with other geographical regions	63
4.4	Analysis of Dihydrofolate Reductase (<i>dhfr</i>) And Dihydropteroate Synthase (<i>dhps</i>) Genes In <i>Plasmodium vivax</i> From Sabah Isolates	68
4.4.1	Sequence polymorphisms of <i>Plasmodium vivax dhfr</i> (<i>pvdhfr</i>) gene	68
4.4.2	Sequence polymorphisms of <i>Plasmodium vivax dhps</i> (<i>pvdhps</i>) gene	72
4.4.3	Prevalence of haplotype conferring resistance in dihydrofolate reductase (<i>dhfr</i>) and dihydropteroate synthase (<i>dhps</i>) genes of <i>P. vivax</i>	75
4.4.4	Comparison of haplotype-conferring resistant in <i>dhfr</i> and <i>dhps</i> genes of <i>P. vivax</i> from Sabah isolates with other geographical regions	76
4.5	Analysis of Dihydrofolate Reductase (<i>dhfr</i>) And Dihydropteroate Synthase (<i>dhps</i>) Genes In <i>Plasmodium knowlesi</i> From Sabah Isolates	81
4.5.1	Sequence polymorphisms of <i>Plasmodium knowlesi dhfr</i> (<i>pkdhfr</i>) gene	81
4.5.2	Sequence polymorphisms of <i>Plasmodium knowlesi dhps</i> (<i>pkdhps</i>) gene	86
4.5.3	Haplotypes-conferring resistance in dihydrofolate reductase (<i>dhfr</i>) and dihydropteroate synthase (<i>dhps</i>) genes of <i>P. knowlesi</i>	90
4.5.4	Comparison of <i>dhfr</i> and <i>dhps</i> genes in <i>P. knowlesi</i> from around the world with Sabah isolates	90

CHAPTER 5: DISCUSSION

5.1	Study Population	93
-----	------------------	----

5.2	Prevalence of Point Mutations In Antifolate Drug Resistance Genes	94
5.2.1	Mutations conferring resistance in <i>P. falciparum dhfr</i> and <i>dhps</i> genes from Sabah isolates	94
5.2.2	Mutations conferring resistance in <i>P. vivax dhfr</i> and <i>dhps</i> genes from Sabah isolates	96
5.2.3	Mutations conferring resistance in <i>P. knowlesi dhfr</i> and <i>dhps</i> genes from Sabah isolates	98
5.3	Distribution of Mutant Alleles At <i>dhfr</i> And <i>dhps</i> Genes In <i>P. falciparum</i> Sabah Isolates	99
5.4	Distribution of Mutant Alleles At <i>dhfr</i> And <i>dhps</i> Genes In <i>P. vivax</i> Sabah Isolates	101
5.5	Limitations of The Study And Possible Future Research	102
CHAPTER 6: CONCLUSION		104
REFERENCE		106
APPENDIX 1		126
APPENDIX 2		128



LIST OF TABLES

	Page
Table 3.1: Primers used in Nest 1 <i>Plasmodium</i> genus-specific PCR	31
Table 3.2: Primers used in Nest 2 <i>Plasmodium</i> genus-specific PCR	32
Table 3.3: Primers used in Nest 2 <i>Plasmodium</i> species-specific PCR amplification reactions	34
Table 3.4: Primers used in Nest 1 and Nest 2 PCR amplification reaction <i>dhfr</i> and <i>dhps</i> genes in <i>Plasmodium falciparum</i>	37
Table 3.5: Primers used in Nest 1 and Nest 2 PCR amplification reaction of <i>dhfr</i> and <i>dhps</i> genes in <i>Plasmodium vivax</i>	39
Table 3.6: Primers used in Nest 1 and Nest 2 PCR amplification reaction of <i>dhfr</i> and <i>dhps</i> genes in <i>Plasmodium knowlesi</i>	40
Table 4.1: Position of nucleotide polymorphisms in <i>pfdhfr</i> gene	53
Table 4.2: Single nucleotide polymorphisms of <i>P. falciparum dhfr</i> gene as compared to the reference <i>P. falciparum</i> 3D7 (XM_001351443)	54
Table 4.3: Prevalence of point mutations in <i>pfdhfr</i> gene Sabah isolates	55
Table 4.4: Position of nucleotide polymorphisms in <i>pfdhps</i> gene	57
Table 4.5: Single nucleotide polymorphisms of <i>P. falciparum dhps</i> gene as compared to the reference <i>P. falciparum</i> 3D7 (XM_001349382)	58
Table 4.6: Prevalence of point mutations in <i>P. falciparum dhps</i> gene	59
Table 4.7: Prevalence of haplotypes in <i>P. falciparum dhfr</i>	61
Table 4.8: Prevalence of haplotypes in <i>P. falciparum dhps</i>	62
Table 4.9: Prevalence of allele combination of <i>pfdhfr-pfdhps</i>	62

Table 4.10:	Comparison of <i>pfdhfr</i> haplotypes from different geographical regions	64
Table 4.11:	Comparison of <i>pfdhps</i> haplotypes from different geographical regions	66
Table 4.12:	Position of nucleotide polymorphisms in <i>pvdhfr</i> gene	68
Table 4.13:	Single nucleotide polymorphisms of <i>P. vivax dhfr</i> gene as compared to the reference Sal-1 (XM_001615032)	69
Table 4.14:	Prevalence of point mutations in <i>P. vivax dhfr</i> gene	70
Table 4.15:	Position of nucleotide polymorphisms in <i>pvdhps</i> gene	72
Table 4.16:	Single nucleotide polymorphisms of <i>P. vivax dhps</i> gene as compared to the reference Sal-1 (XM_001617159)	72
Table 4.17:	Prevalence of point mutations in <i>P. vivax dhps</i> gene	73
Table 4.18:	Prevalence of haplotypes in <i>P. vivax dhfr</i>	75
Table 4.19:	Prevalence of haplotypes in <i>P. vivax dhps</i>	76
Table 4.20:	Prevalence of allele combination of <i>pvdhfr-pvdhps</i>	76
Table 4.21:	Comparison of <i>pvdhfr</i> haplotypes from different geographical regions	77
Table 4.22:	Comparison of <i>pvdhps</i> haplotypes from different geographical regions	80
Table 4.23:	Position of nucleotide polymorphisms in <i>pkdhfr</i> gene	82
Table 4.24:	Most frequent single nucleotide polymorphisms (SNPs) detected at <i>pkdhfr</i> gene in Sabah isolates as compared to the reference (XM_002258192)	83
Table 4.25:	Prevalence of point mutations in <i>P. knowlesi dhfr</i> gene	84
Table 4.26:	Position of nucleotide polymorphisms in <i>pkdhps</i> gene	86
Table 4.27:	Single nucleotide polymorphisms (SNPs) detected at <i>pkdhps</i> gene Sabah isolates as compared to the reference (XM_002262146)	87
Table 4.28:	Prevalence of point mutations in <i>P. knowlesi dhps</i> gene	88
Table 4.29:	Comparison of <i>pkdhfr</i> nucleotide sequences from different geographical regions	92

LIST OF FIGURES

	Page
Figure 2.1: Microscopic morphology of <i>Plasmodium falciparum</i> parasites	9
Figure 2.2: Microscopic morphology of <i>Plasmodium vivax</i> parasites	10
Figure 2.3: Microscopic morphology of <i>Plasmodium malariae</i> parasites	11
Figure 2.4: Microscopic morphology of <i>Plasmodium ovale</i> parasites	12
Figure 2.5: Microscopic morphology of <i>Plasmodium knowlesi</i> parasites	14
Figure 2.6: The life cycle of malaria parasite includes six main stages: sporozoites, liver stage, human blood cell cycle, sexual stage, early mosquito stages, and late mosquito stages	16
Figure 2.7: Structure of sulfanilamide (sulfadoxine) which contain N1 -(5,6-dimethoxy-4-pyrimidinyl), and pyrimethamine containing 2,4-diamino-5-(p-chlorophenyl)-6-ethylpyrimidine	19
Figure 3.1: Map of Sabah. Study site of malaria sample collection including Kudat, Kota Kinabalu, and Keningau, Sabah	28
Figure 4.1: Total number of sample collection from three different study areas	45
Figure 4.2: Results of <i>Plasmodium</i> species-specific nested PCR among the studied isolates	46
Figure 4.3: Number of single infection of <i>Plasmodium</i> sp. based on study sites	47
Figure 4.4: 2.0% agarose gel electrophoresis for PCR amplification of <i>P. falciparum</i>	48

Figure 4.5:	2.0% agarose gel electrophoresis for PCR amplification of <i>P. vivax</i>	48
Figure 4.6:	2.0% agarose gel electrophoresis for PCR amplification of <i>P. malariae</i>	49
Figure 4.7:	2.0% agarose gel electrophoresis for PCR amplification of <i>P. knowlesi</i>	50
Figure 4.8:	1.5% gel electrophoresis for amplification of (a) <i>P. falciparum dhps</i> gene, 728 bp and (b) <i>P. falciparum dhfr</i> gene, 648 bp	51
Figure 4.9:	1.5% gel electrophoresis for amplification of (a) <i>P. vivax dhfr</i> gene, 1796 bp and (b) <i>P. vivax dhps</i> gene, 2498 bp	51
Figure 4.10:	1.5% gel electrophoresis for amplification of (a) <i>P. knowlesi dhfr</i> gene, 1787 bp and (b) <i>P. knowlesi dhps</i> gene, 2178 bp.	52
Figure 4.11:	Location of point mutations of the <i>pfdhfr</i> gene	56
Figure 4.12:	Location of point mutations of the <i>pfdhps</i> gene	60
Figure 4.13:	Location of mutations of the <i>pvdhfr</i> gene	71
Figure 4.14:	Location of mutations of the <i>pvdhps</i> gene	74
Figure 4.15:	Location of mutations of the <i>pkdhfr</i> gene	85
Figure 4.16:	Location of mutations of the <i>pkdhps</i> gene	89

LIST OF PHOTOS

Photo 3.1 : Patients' dried blood spots

Page
29



UMS
UNIVERSITI MALAYSIA SABAH

LIST OF APPENDIX

	Page
Appendix 1 Approval letter for ethical clearance	120
Appendix 2 Details of the collected samples and nested PCR results	122



UMS
UNIVERSITI MALAYSIA SABAH

LIST OF SYMBOLS AND ABBREVIATIONS

%	-	Percentage
mm	-	Millimeter
cm	-	Centimeter
x	-	Times
ml	-	Milliliter
min	-	Minute
sec	-	Second
U	-	Unit
μl	-	Microliter
μM	-	Micromolar
°C	-	Degree celcius
V	-	Voltage
kb	-	Kilobase
bp	-	Basepair
M	-	Molar
mM	-	Milimolar
rpm	-	Revolution per minute
MgCl ₂	-	Magnesium chloride
dNTPs	-	Deoxynucleotide triphosphates
DNA	-	Deoxyribonucleic acid
<i>dhfr</i>	-	Dihydrofolate reductase
<i>dhps</i>	-	Dihydropteroate synthase
SNPs	-	Single nucleotide polymorphisms
Cds	-	Coding sequence

CHAPTER 1

INTRODUCTION

1.1 Background of Research

The emergence of infectious disease agents in human beings is increasingly important in public health. Malaria is one of the most challenging infectious diseases that captured most of the global attention. In most remote and underdeveloped regions of the world, malaria remains as a health problem (Cox-Singh, 1997) and become the most prevalent and most harmful blood parasitic disease of humans (White, 2004) with an estimated 214 million number of cases and 438 000 deaths by year 2015 (WHO, 2015).

Malaria is caused by single-celled organisms which are known as protozoan parasites of the genus *Plasmodium*. This protozoan parasite cannot survive in condition of less oxygen availability (Atherson, 2012). The parasite is carried by the female *Anopheles* mosquitoes which act as a vector and is transmitted by the bite of the infected mosquitoes. Five major species of *Plasmodium* that responsible for causing malaria disease in humans are *P. falciparum*, *P. vivax*, *P. malariae*, *P. ovale*, and *P. knowlesi* (Atherson, 2012).

Fever, shivering, cough, respiratory distress, pain in the joints, headache, watery diarrhea, vomiting and convulsions are the common symptoms of malaria infection. These symptoms can develop within six to eight days after the infection from mosquito bite (Miller *et al.*, 2002). Untreated malaria infection can quickly become a serious threat to patient's life and often leading to death (WHO, 2015).

Malaria had been eliminated or effectively suppressed in many parts of the world. However, in poor countries in the tropics, malaria has resurged due to the

lack of enforcement as well as the failure of the global eradication campaign in year 1960s (White, 2004).

1.2 Antimalarials Resistance: Facing the Problem

In the past four decades, the global resurgence of malaria has been contributed mainly by the development of resistance (Marsh, 1998). Antimalarial resistance is becoming an increasingly important factor in the effective treatment of malaria. Chloroquine is highly resistant in *P. falciparum* in most of the areas that were affected by malaria. Widespread of sulphadoxine-pyrimethamine resistance and their rapid development were also reported while resistance in mefloquine was found only in areas where it has been used extensively such as Thailand, Cambodia and Vietnam (Nosten *et al.*, 2000).

Treatment failure due to resistance in malaria parasite with chloroquine has already become a pressing problem in malaria management since many years ago (Greenberg *et al.*, 1989; Trape *et al.*, 1998) which best explains the increase number of malaria mortality among children in eastern and southern Africa (Korenromp *et al.*, 2003). Similar results will likely happen with the increasing resistance to antifolates drug such as sulphadoxine-pyrimethamine where it has been used as the first-line treatment of malaria disease after chloroquine (Gregson and Plowe, 2005). In East Malaysia, chloroquine is no longer used as the first line treatment for uncomplicated *P. falciparum* due to high prevalence of the *pfcr* K76T mutants among *P. falciparum* isolates from Sabah. The treatment was then replaced by sulphadoxine-pyrimethamine and followed by artemisinin combinational therapy (ACTs) recently (Cox-Singh *et al.*, 2003; Nor Azrina *et al.*, 2011; Atroosh *et al.*, 2012).

Resistance to sulphadoxine-pyrimethamine has been reported to be associated with specific mutations at dihydrofolate reductase (*dhfr*) and dihydropteroate synthase (*dhps*) genes. These two genes encode the enzymes involved in the folate pathway targeted by existing antifolate drugs (Bzik *et al.*,

1987; Brooks *et al.*, 1994; Triglia and Cowman, 1994). Both genes have been cloned and sequenced, and the discoveries of mutations in these genes have been determined to be associated with resistance against antifolate drugs (Peterson *et al.*, 1988). Interruption of folate synthesis by these two genes inhibitors will cause decreasing levels of fully reduced tetrahydrofolate which is an important cofactor in biosynthetic pathways of purine, pyrimidine, and amino acid (Ferone, 1977).

1.3 Research Question

Studies to determine the prevalence of molecular markers for antimalarial drug resistance in Sabah already started more than ten years ago. Given that the effectiveness of widely used antimalarials such as sulphadoxine-pyrimethamine is not promising, a study to characterize the drug related polymorphism in malaria parasites in Sabah would be timely. There are two research questions that will need to be answered by this study:

- i. Do mutations at both loci *dhfr* and *dhps* exist in *Plasmodium* parasites isolated from Sabah population?
- ii. Do mutations conferring resistance in *P. knowlesi* orthologues of the *P. falciparum* and *P. vivax* genes exist?
- iii. Are there novel mutations detected at both *dhfr* and *dhps* genes in *Plasmodium* parasites isolated from Sabah population?

1.4 Hypothesis of the Study

Mutations in the gene *dhfr* and *dhps* that confers to the antimalarial drug resistance are present in the *Plasmodium* isolates across Sabah.

1.5 Objectives of the Study

This study aimed to achieve the following objectives:

- i. To characterize *dhfr* and *dhps* genes in *P. falciparum*, *P. vivax* and *P. knowlesi* from Sabah isolates.
- ii. To identify single nucleotide polymorphisms in *P. knowlesi* orthologues of the *P. falciparum* and *P. vivax* genes associated with antimalarial drug resistance.
- iii. To detect novel mutations of antimalarial drug resistance markers in *dhfr* and *dhps* genes of *P. falciparum*, *P. vivax* and *P. knowlesi* isolates in the stated areas of Sabah.

1.6 Significance of the Study

Previous studies have been carried out to determine the prevalence of molecular markers for antimalarial drug resistance in *Plasmodium falciparum* Sabah isolates (Cox-Singh *et al.*, 2001; Nor Azrina *et al.*, 2011; Noor Rain *et al.*, 2013; Lau *et al.*, 2013). Understanding the genetic basis of drug resistance is essential for implementing rational measures to overcome the increase number of resistance in the widely used antimalarials. Genetic information can be used for early detection of resistance loci as well as for future monitoring of drug resistant malaria. Hence, genotyping genetic loci associated with drug resistance genes are a potentially useful epidemiological tool in conjunction with the conventional *in-vitro* and *in-vivo* drug-sensitivity assessments. Findings from this study may modulate drug resistance or response in *P. vivax*, *P. knowlesi*, and reassess polymorphisms in *P. falciparum* in Sabah. The prevalence data of various mutations in this study will provide the first time information on polymorphisms on *P. knowlesi* orthologous genes associated with resistance in antifolate drug particularly the sulphadoxine-pyrimethamine.